Relatlimab
Relatlimab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Non-small Cell Lung Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
5 项
已进入 III/IV 期
26 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Bristol-Myers Squibb
- Carlo Contreras
- University of Wisconsin, Madison
- National Cancer Institute (NCI)
- Linnaeus Therapeutics, Inc.
- H. Lee Moffitt Cancer Center and Research Institute
- M.D. Anderson Cancer Center
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、加拿大、荷兰、澳大利亚、意大利、比利时、中国、法国、德国、中国香港、爱尔兰、日本
正在招募患者的 Relatlimab 研究
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
I 期招募中美国NCT04697576Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
I 期 / II 期招募中美国NCT07281924Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
II 期 / III 期招募中美国加拿大NCT05987241A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
II 期 / III 期招募中美国NCT06624644Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
II 期招募中美国NCT06295159Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
II 期招募中美国NCT05704647Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
II 期招募中美国NCT03521830Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer
II 期招募中荷兰NCT03026140Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
II 期招募中美国NCT06712927Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma
II 期招募中澳大利亚NCT06288191Study to Evaluate Impact® as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic Melanoma
不适用招募中意大利NCT06880198IL-17 Blockade to Decrease irAEs (REPLAY)
I 期招募中美国NCT07237594A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
II 期招募中美国比利时加拿大中国NCT07492680Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
II 期招募中美国NCT05428007IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
III 期招募中美国Argentina澳大利亚奥地利NCT06112314A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
III 期招募中美国加拿大NCT06246916Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
II 期招募中澳大利亚NCT06151236Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
II 期招募中澳大利亚NCT06999980VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
III 期招募中美国法国德国GreeceNCT06264180Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
II 期招募中美国NCT06624475Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin
II 期招募中奥地利NCT04204837Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
I 期 / II 期招募中美国NCT06683755Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
II 期招募中美国澳大利亚加拿大中国香港NCT06029270ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
II 期招募中美国NCT07504796
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。